Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
CONCLUSIONS: Our call to action is to expand access to comprehensive genomic testing, foster a learning health care system, enable fast and equitable access to cost-effective treatments, and ultimately improve health outcomes.PMID:38630538 | DOI:10.1093/oncolo/oyae060 (Source: The Oncologist)
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Priscila Radu Gayathri Kumar Amanda Cole Aikaterini Fameli Mark Guthrie Lieven Annemans Jan Geissler Antoine Italiano Brian O'Rourke Entela Xoxi Lotte Steuten Source Type: research

Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens
CONCLUSION: Smoking status does not appear to independently influence the clinical outcomes to first-line ICI-based regimens in patients with mRCC. Nonetheless, patient counseling on tobacco cessation remains a crucial aspect of managing patients with mRCC, as it significantly reduces all-cause mortality.PMID:38630540 | DOI:10.1093/oncolo/oyae072 (Source: The Oncologist)
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Eddy Saad Georges Gebrael Karl Semaan Marc Eid Ren ée Maria Saliby Chris Labaki Nicolas Sayegh J Connor Wells Kosuke Takemura Matthew Scott Ernst Audreylie Lemelin Naveen S Basappa Lori A Wood Thomas Powles D Scott Ernst Aly-Khan A Lalani Neeraj Agarwal Source Type: research

Human malignancies associated with persistent HPV infection
Oncologist. 2024 Apr 17:oyae071. doi: 10.1093/oncolo/oyae071. Online ahead of print.ABSTRACTHuman papillomavirus (HPV)-associated malignancies account for ~5% of human cancers worldwide. Thirteen, or more, HPV types are oncogenic, but infection with these viruses is common and usually cleared within 2 years. Only infections that become persistent are associated with the development of cancer, often occurring several decades later. These cancers mostly arise in 6 different anatomical regions: 5 are anogenital (anus, cervix, penis, vagina, and vulva) and the sixth is the oropharynx. Oncogenic HPVs promote cellular proliferat...
Source: The Oncologist - April 17, 2024 Category: Cancer & Oncology Authors: Alison A McBride Source Type: research

Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma
CONCLUSION: Our study shed light on the potential comorbidity patterns in elderly patients with NPC, thereby providing valuable insights into the development of comprehensive health management strategies for this specific population.PMID:38625619 | DOI:10.1093/oncolo/oyae063 (Source: The Oncologist)
Source: The Oncologist - April 16, 2024 Category: Cancer & Oncology Authors: Ying Li Yuhui Pan Zongwei Huang Lishui Wu Wenxi Wu Siqi Xu Zihan Chen Xin Chen Jun Lu Sufang Qiu Source Type: research

Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma
CONCLUSION: Our study shed light on the potential comorbidity patterns in elderly patients with NPC, thereby providing valuable insights into the development of comprehensive health management strategies for this specific population.PMID:38625619 | DOI:10.1093/oncolo/oyae063 (Source: The Oncologist)
Source: The Oncologist - April 16, 2024 Category: Cancer & Oncology Authors: Ying Li Yuhui Pan Zongwei Huang Lishui Wu Wenxi Wu Siqi Xu Zihan Chen Xin Chen Jun Lu Sufang Qiu Source Type: research

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Oncologist. 2024 Apr 10:oyae062. doi: 10.1093/oncolo/oyae062. Online ahead of print.ABSTRACTFor cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from a defined centralized clinical trial assay to assign patients to a therapeutic substudy, we developed a process to repurpose existing commercial vendor raw genomic data for eligibility: genomic data reanalysis (GDR). Molecular results for substudy assignment were successfully generated for 369 of the first 374 pat...
Source: The Oncologist - April 10, 2024 Category: Cancer & Oncology Authors: Joel W Neal Katherine Minichiello Ryan Brennick Richard S P Huang Matthew C Hiemenz Cornel Amler Jyoti Patel Roy Herbst Karen L Reckamp Hossein Borghaei Louise Highleyman Mary W Redman Lincoln W Pasquina David E Kozono Source Type: research

Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)
CONCLUSION: The final analysis confirmed the efficacy of nivolumab monotherapy for patients with advanced GC in routine clinical practice. The exploratory analysis indicated that increasing DpR was associated with longer median PFS and OS in nivolumab treatment at a later-line setting.PMID:38581687 | DOI:10.1093/oncolo/oyae056 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Sunakawa Yasuhiro Sakamoto Ryohei Kawabata Atsushi Ishiguro Yusuke Akamaru Yosuke Kito Masazumi Takahashi Jin Matsuyama Hiroshi Yabusaki Akitaka Makiyama Takahisa Suzuki Masahiro Tsuda Hisateru Yasui Jun Hihara Atsushi Takeno Eisuke Inoue Wataru Ichika Source Type: research

Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
CONCLUSION: EA consolidation chemotherapy for transplant-ineligible, elderly patients with PCNSL improved response rates but showed a high relapse rate and short progression-free survival. The incidences of treatment-related mortality caused by hematologic toxicities and severe infections were very high, even after dose modification. Therefore, the use of EA consolidation should be reconsidered in elderly patients with PCNSL.PMID:38581718 | DOI:10.1093/oncolo/oyae059 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Ri Kim Hyunsoo Cho Soo-Jeong Kim Haerim Chung Hye Won Kook Ji Eun Jang June-Won Cheong Jin Seok Kim Source Type: research

Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)
CONCLUSION: The final analysis confirmed the efficacy of nivolumab monotherapy for patients with advanced GC in routine clinical practice. The exploratory analysis indicated that increasing DpR was associated with longer median PFS and OS in nivolumab treatment at a later-line setting.PMID:38581687 | DOI:10.1093/oncolo/oyae056 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Sunakawa Yasuhiro Sakamoto Ryohei Kawabata Atsushi Ishiguro Yusuke Akamaru Yosuke Kito Masazumi Takahashi Jin Matsuyama Hiroshi Yabusaki Akitaka Makiyama Takahisa Suzuki Masahiro Tsuda Hisateru Yasui Jun Hihara Atsushi Takeno Eisuke Inoue Wataru Ichika Source Type: research

Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
CONCLUSION: EA consolidation chemotherapy for transplant-ineligible, elderly patients with PCNSL improved response rates but showed a high relapse rate and short progression-free survival. The incidences of treatment-related mortality caused by hematologic toxicities and severe infections were very high, even after dose modification. Therefore, the use of EA consolidation should be reconsidered in elderly patients with PCNSL.PMID:38581718 | DOI:10.1093/oncolo/oyae059 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Ri Kim Hyunsoo Cho Soo-Jeong Kim Haerim Chung Hye Won Kook Ji Eun Jang June-Won Cheong Jin Seok Kim Source Type: research

Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)
CONCLUSION: The final analysis confirmed the efficacy of nivolumab monotherapy for patients with advanced GC in routine clinical practice. The exploratory analysis indicated that increasing DpR was associated with longer median PFS and OS in nivolumab treatment at a later-line setting.PMID:38581687 | DOI:10.1093/oncolo/oyae056 (Source: The Oncologist)
Source: The Oncologist - April 6, 2024 Category: Cancer & Oncology Authors: Yu Sunakawa Yasuhiro Sakamoto Ryohei Kawabata Atsushi Ishiguro Yusuke Akamaru Yosuke Kito Masazumi Takahashi Jin Matsuyama Hiroshi Yabusaki Akitaka Makiyama Takahisa Suzuki Masahiro Tsuda Hisateru Yasui Jun Hihara Atsushi Takeno Eisuke Inoue Wataru Ichika Source Type: research